Overview of Multiple Myeloma Treatment Options
The treatment landscape for multiple myeloma has significantly evolved, incorporating a diverse range of therapeutic agents and combinations.
The five year survival has reached 64% with novel agents.
This progression has been driven by novel drug classes and optimized treatment regimens.
Treatment assessment utilizes disease risk stratification, potential consolidation with transplant, long-term maintenance therapy, and a goal of achieving and sustaining a state of minimal measurable residual disease.
Common Therapeutic Classes
Monoclonal Antibodies Examples: Daratumumab, Elotuzumab, isatuximab
Proteasome Inhibitors (PIs)** Examples: Bortezomib, Carfilzomib, Ixazomib
Drugs (IMiDs)** Examples: Lenalidomide, Thalidomide, Pomalidomide
Histone Deacetylase Inhibitors** – Example: Panobinostat
Emerging Treatments** Cereblon-modulating agents Chimeric Antigen Receptor (CAR) T Cells T cell-engaging bispecific antibodies Antibody-drug conjugates
Treatment Strategies for Newly Diagnosed Patients
Eligible for Autologous Stem Cell Transplantation (ASCT)
Recommended Induction Therapy: Triplet regimen of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Follow-up with ASCT and maintenance therapy using Lenalidomide.
Ineligible for ASCT** Preferred Regimen: Combination of Daratumumab, Lenalidomide, and Dexamethasone (DRd).
Approaches for Relapsed or Refractory Cases – The selection of therapy depends on: – Prior treatments – Duration and quality of previous response
Standard Options: Monoclonal antibody-based regimens combined with an IMiD and/or a PI are recommended.
– Triplet regimens are preferred if tolerated, as they generally provide superior efficacy over doublet regimens.
Examples of Triplet Regimens: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Daratumumab, Bortezomib, and additional agents depending on prior therapy
Triplet combinations enhance both progression-free survival and overall response rates compared to doublet regimens.
The choice of specific agents and therapeutic combinations is tailored to the patient’s previous treatments, comorbidities, and overall health status.
This systematic approach to managing multiple myeloma emphasizes personalized care to optimize outcomes for each patient.
Quadruple induction therapy followed by autologous stem cell transplantation is the standard of care for a transplant eligible patient with newly diagnosed multiple myeloma.
Studies have shown in newly diagnosed patients with multiple myeloma progression free survival in patients treated with bortezomib, lenalidomide, dexamethasone and daratumumab or isatuximab was superior to Vrd alone.
The Dara-VRd is the standard of care in 2025, and maybe followed by autologous stem cell transplant and maintenance therapy typically with lenalidomide.
The Dara-VRd regimen increased the four year estimated progression free survival rate from 67.7% to 84.3% among transplant, eligible patients with newly diagnosed myeloma compared to a three drug regimen.
In previously treated patients with multiple myeloma who had received 1 to 3 previous lines of therapy patients treated with teclistamab-daratumumab had a significantly longer progression free survival than those treated with dexamethasone pomalidomide or boerezomib combined with daratumumab.
Measurable residual disease (MRD) is a major prognostic factor for newly diagnose multiple myeloma.
Among patients who were MRD negative at 10 to the fifth sensitivity after induction the percentage with a pre-maintenance MRD negative status at 10 to the -6th sensitivity was not significantly higher with allogeneic stem cell transplant than with four drug treatment Isa-KRD.
MRD negative status at 10 to the fifth sensitivity is less than one cancer cell per hundred thousand normal cells and 10 to the six sensitivity is less than one cancer cell per million.
MRD assessment provides the strongest prognostic factor for patients in myeloma.
Randomized trials of modern triplet or quadruplet therapy composed of immunomodulatory drugs, such as lenalidomide, proteosome inhibitors, and glucocorticoids have not shown an overall survival benefit with the addition of high dose melphalan- ASCT.
Among newly diagnosed patients with multiple myeloma treated with early total therapy protocols it is estimated that at least one of three patients can be cured.
For relapsed and refractory myeloma major therapeutic advancement has occurred with the use of CART-cell therapy.
In the CARTITUDE-1 trial, ciltacabtagene autoleucil single infusion resulted in 1/3 of patients remaining progressive progression free with durable responses in patients with aberrant TP 53 and high risk cytogenetics.